announced today that GRALISE^ tablets are now available as a new once-daily treatment for postherpetic neuralgia, the pain following healing of the rash associated with shingles. GRALISE is available by prescription in a 30-day starter pack, which allows titration of the drug to full dose in 15 days, as well as bottles of 600 mg and 300 mg tablets. GRALISE is a proprietary formulation of gabapentin, using patented polymer technology that enables gradual release of the drug. GRALISE has a favorable safety profile. GRALISE has no branded or generic equivalent and is not interchangeable with other gabapentin products.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.